Jan. 9 at 12:10 AM
$MESO Mesoblast just delivered a very strong commercial update. Ryoncil sales jumped 60% QoQ to US
$35.1M, confirming real revenue momentum, not just promise. The company has cleaned up its balance sheet, repaid old expensive debt, and locked in a flexible US
$125M facility without putting IP or assets at risk. Importantly, Ryoncil is already FDA-approved and selling, with the adult indication now in trials, which management says is a market ~3x larger than pediatrics. Strong sales, improving finances, long patent life (to 2044+), and upcoming adult expansion make this one of the clearest biotech commercialisation stories on the ASX.
